Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 0.70 |
| ▸ | MMP1 | P03956 | 17/20 | 0.70 |
| ▸ | PGR | P06401 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7812 | 0.91 | NR3C1 (0.73) | NR3C1MMP1PGRMEN1USP2 | |
| Betamethasone Benzoate SCHEMBL11878006 | 0.91 | NR3C1 (0.77) | NR3C1MMP1PGRMEN1USP2 | |
| Betamethasone Benzoate SCHEMBL11877997 | 0.91 | NR3C1 (0.77) | NR3C1MMP1PGRMEN1USP2 | |
| Betamethasone Benzoate SCHEMBL49469 | 0.91 | NR3C1 (0.77) | NR3C1MMP1PGRMEN1USP2 | |
| Betamethasone Benzoate SCHEMBL2954925 | 0.91 | NR3C1 (0.77) | NR3C1MMP1PGRMEN1USP2 | |
| Betamethasone Benzoate SCHEMBL21682645 | 0.90 | NR3C1 (0.77) | NR3C1MMP1PGRMEN1USP2 | |
| SCHEMBL4102916 | 0.86 | NR3C1 (0.72) | NR3C1MMP1PGRMEN1USP2 | |
| SCHEMBL11037864 | 0.86 | NR3C1 (0.72) | NR3C1MMP1PGRMEN1USP2 | |
| Betamethasone Benzoate SCHEMBL6898101 | 0.86 | NR3C1 (0.88) | NR3C1MMP1PGRMEN1USP2 | |
| SCHEMBL6986508 | 0.86 | NR3C1 (0.83) | NR3C1MMP1PGRMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133513-A1 | COMPOSITION AND PRODUCTS COMPRISING AN ANTIBIOTIC AND A GLUCOCORTICOID FOR TREATING MASTITIS | VIRBAC (FR) | 2024-06-27 | — | — | WO | disclosed |
| US-20240016818-A1 | NOVEL USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF EPITHELIAL MICROBIAL INFECTIONS OF A FLUID CONTAINING ORGAN WITH A NATURAL EXTERIOR ORIFICE IN MAMMALS | VIRBAC (FR) | 2024-01-18 | — | — | US | disclosed |
| US-11819506-B2 | Use of glucocorticoids for the treatment of epithelial microbial infections of a fluid containing organ with a natural exterior orifice in mammals | VIRBAC (FR) | 2023-11-21 | — | — | US | disclosed |
| US-20220008439-A1 | NOVEL USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF EPITHELIAL MICROBIAL INFECTIONS OF A FLUID CONTAINING ORGAN WITH A NATURAL EXTERIOR ORIFICE IN MAMMALS | VIRBAC (FR) | 2022-01-13 | — | — | US | disclosed |
| US-20210386758-A1 | TOPICAL FORMULATIONS COMPRISING A STEROID | PRIMUS PHARMACEUTICALS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-11179465-B2 | Topical compositions comprising a corticosteroid | PRIMUS PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3829591-A1 | NOVEL USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF EPITHELIAL MICROBIAL INFECTIONS OF A FLUID CONTAINING ORGAN WITH A NATURAL EXTERIOR ORIFICE IN MAMMALS | VIRBAC (FR) | 2021-06-09 | — | — | EP | disclosed |
| CN-112512528-A | Novel use of glucocorticoids for treating epithelial microbial infections of fluid-containing organs with natural exterior orifice in mammals | 维克公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20210069214-A1 | TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID FOR THE TREATMENT OF PSORIASIS IN PEDIATRIC PATIENTS | ENCORE DERMATOLOGY, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021046444-A1 | TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID FOR THE TREATMENT OF PSORIASIS IN PEDIATRIC PATIENTS | ENCORE DERMATOLOGY, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20160235767-A1 | TOPICAL FORMULATIONS COMPRISING A STEROID | PRIMUS PHARMACEUTICALS, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160199493-A1 | TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID | PRIMUS PHARMACEUTICALS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160184431-A1 | TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID | PROMIUS PHARMA LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-9364485-B2 | Topical formulations comprising a steroid | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-06-14 | — | — | US | disclosed |
| US-20160030450-A1 | TOPICAL CORTICOSTEROID COMPOSITIONS | PROMIUS PHARMA LLC | 2016-02-04 | — | — | US | disclosed |
| US-20150258119-A1 | TOPICAL CORTICOSTEROID COMPOSITIONS | Promius Pharma, LLC | 2015-09-17 | — | — | US | disclosed |
| WO-2015138650-A1 | TOPICAL CORTICOSTEROID COMPOSITIONS | Promius Pharma, LLC (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20120214776-A1 | TOPICAL FORMULATIONS COMPRISING A STEROID | DR. REDDY'S LABORATORIES, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| EP-2473161-A2 | TOPICAL FORMULATIONS COMPRISING A STEROID | Dr. Reddy's Laboratories Ltd. (IN) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026076-A2 | TOPICAL FORMULATIONS COMPRISING A STEROID | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030450-A1 | TOPICAL CORTICOSTEROID COMPOSITIONS | NR5A1, NR3C1, SERPINA6 | NR3C1 2/4885MMP1 155/4885PGR 597/4885 |
| US-20210069214-A1 | TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID FOR THE TREATMENT OF PSORIASIS IN PEDIATRIC PATIENTS | TSLP, IL17A, IL5 | NR3C1 7/4885MMP1 504/4885PGR 420/4885 |
| US-20160235767-A1 | TOPICAL FORMULATIONS COMPRISING A STEROID | NR5A1, CYP17A1, TSLP | NR3C1 11/4885MMP1 289/4885PGR 233/4885 |
| US-11179465-B2 | Topical compositions comprising a corticosteroid | NR5A1, NR3C1, CYP17A1 | NR3C1 2/4885MMP1 65/4885PGR 442/4885 |
| US-20160199493-A1 | TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID | NR3C1, NR5A1, TSLP | NR3C1 1/4885MMP1 76/4885PGR 74/4885 |
| US-20210386758-A1 | TOPICAL FORMULATIONS COMPRISING A STEROID | NR5A1, CYP17A1, TSLP | NR3C1 11/4885MMP1 289/4885PGR 233/4885 |
| US-20120214776-A1 | TOPICAL FORMULATIONS COMPRISING A STEROID | NR5A1, CYP17A1, TSLP | NR3C1 11/4885MMP1 289/4885PGR 233/4885 |
| US-20160184431-A1 | TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID | NR3C1, NR5A1, TSLP | NR3C1 1/4885MMP1 76/4885PGR 74/4885 |
| US-20150258119-A1 | TOPICAL CORTICOSTEROID COMPOSITIONS | NR5A1, NR3C1, NR3C2 | NR3C1 2/4885MMP1 192/4885PGR 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.